Bayer and Exscientia, an Artificial Intelligence (AI) – driven drug discovery company, have entered into a three-year multi-target collaboration. They aim to identify and optimize novel lead structures for drug candidates to treat cardiovascular and oncological diseases. AI has the potential to accelerate drug discovery and improve drug development productivity in terms of quality, cost and cycle time.
https://www.sumeetsud.com/sumeet-sud-shares-news-of-bayer-and-exscientia-collaboration/
https://www.sumeetsud.com/tag/ai/
https://www.sumeetsud.com/tag/artificial-intelligence/
https://www.sumeetsud.com/tag/bayer/
https://www.sumeetsud.com/tag/collaboration/
https://www.sumeetsud.com/tag/exscientia/